There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.
Genetics in Anticoagulant Pharmacotherapy
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
There are many well-established correlations between warfarin dosing and therapeutic endpoints. One realm we’re still working to conquer includes the influence of genetics on the application of warfarin and other medicines. Ann Wittkowsky, PharmD, director of anticoagulation services at the University of Washington Medical Center in Seattle, joins host Dr. Charles Turck to examine the potential impact of genetics in pharmacotherapeutics.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
FCS and SHTG: Are We Meeting the Need?
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?